Document is current
Any future updates will be listed below
-
Authors
Kim, Seungmo
Kim, Yongjoong
Kim, Tae-Sung
Kang, Jae-Hyeok
Yun, In-Yeong
Lee, Eung-Suk
Lee, Eun Ji
Kim, Rae-kwon
Yi, Joo Mi https://orcid.org/0000-0001-8341-330X
Choi, Hye Sook
Song, Jin Woo
Jin, Young Woo
Kim, Min-Jung
Lee, Su-Jae
-
Funding
Funding for this research was provided by:
by the Ministry of Science and ICT (MSIT)
- License Information
-
More Information
Article History
Received: 13 January 2025
Revised: 12 August 2025
Accepted: 1 September 2025
First Online: 2 October 2025
Competing interests
: Y.W.J., M.J.K., and S.J.L. are co-founders and shareholders of FNCT Biotech. H.S.C. is a shareholder of FNCT Biotech. The company has a commercial interest in the development of CSF3-neutralizing antibodies discussed in this study. The authors declare that they are inventors on a patent application related to CSF3-neutralizing antibodies for treating pulmonary fibrosis, which is owned by FNCT Biotech. However, the experiments and analyses presented in this paper were conducted independently, and data integrity was rigorously maintained throughout the research process. The other authors declare that they have no competing interests.
